Advertisement

Advertisement
Skin Cancer
Immunotherapy

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

On July 31, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib...

Gynecologic Cancers

American Cancer Society Updates Guideline for Cervical Cancer Screening

An updated cervical cancer screening guideline from the American Cancer Society has called for less—and more simplified—screening...

Skin Cancer
Immunotherapy

Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial...


Advertisement
COVID-19

Top Scientists Share Early Research on Intersection of COVID-19 and Cancer Care at AACR Virtual Meeting

The American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer took place from July 20 to 22, 2020...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Howard A. Burris III, MD, FACP, FASCO, on the ASCO20 Virtual Scientific Program: After Action Report

Hematologic Malignancies
Symptom Management

Addition of Antithymocyte Globulin to Graft-vs-Host Disease Prophylaxis in Matched Sibling Donor Stem Cell Transplant

In a Chinese trial reported in the Journal of Clinical Oncology, Chang et al found that the addition of antithymocyte globulin to standard graft-vs-host disease prophylaxis reduced the risk of acute graft-vs-host disease in patients undergoing human leukocyte antigen (HLA)-matched sibling donor...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Colorectal Cancer
Immunotherapy

Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease

Pancreatic Cancer

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

In a single-institution retrospective study reported in JAMA Surgery, Perri et al found that first-line FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a higher response rate and subsequent pancreatectomy vs gemcitabine plus nab-paclitaxel in patients with...

Issues in Oncology

Study Finds Lack of Parental Intent to Initiate and Complete HPV Vaccination in the United States

Study results documenting parental hesitancy to begin and complete their child's human papillomavirus (HPV) vaccine series were published by Sonawane et al in The Lancet Public Health. The Centers for Disease Control and Prevention recommends a two-dose HPV vaccination regimen for children if the...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Issues in Oncology

Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?

Myelodysplastic Syndromes

Pevonedistat Plus Azacitidine May Be of Benefit in Higher-Risk Myelodysplastic Syndromes

In higher-risk myelodysplastic syndromes (MDS), a global phase II open-label study found that the combination of pevonedistat plus azacitidine was associated with a trend toward improved event-free survival and numerically longer overall survival, as compared with azacitidine alone, according to...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...